Literature DB >> 18426826

Sialochemical and oxidative analyses in radioactive I131-treated patients with thyroid carcinoma.

Sophia Ish-Shalom1, Lena Durleshter, Elena Segal, Rafael M Nagler.   

Abstract

BACKGROUND: I131 in relatively high doses has been shown in the past to cause damaging salivary effects and oral discomfort in patients. Although lower dosage is now widely accepted, I131 may still be the source of salivary damage over the long-term and subsequent harmful effects on both the oral cavity and the gastrointestinal tract, into which the saliva is swallowed. This study examined the effects of radioactive I131 on salivary gland activity, saliva composition and oxidative profile, and related oral discomfort complaints following thyroidectomy due to carcinoma of thyroid gland.
METHODS: Out of 40 consenting female post-thyroidectomy patients, 23 (mean age 50+/-4 years old) were treated with I131 while 17 (mean age 46+/-4) were not. Whole saliva from all subjects was analyzed for antioxidant and biochemical composition and flow rate.
RESULTS: The salivary flow rates of both groups were similar but their composition differed considerably. Salivary superoxide dismutase enzyme (SOD), total protein, and albumin concentrations were significantly reduced in the treated patients by 40, 25, and 18% respectively (P<0.05), as were all other salivary antioxidants. Oral discomfort complaints were far more prevalent in the I131-treated patients.
CONCLUSIONS: I131-dependent damage to the salivary glands was evidenced by a broad spectrum of compositional alterations and oral complaints. Reduction in salivary antioxidant status, SOD enzyme, and the uric acid molecule leaves the oral cavity less protected against oxidative stress. This is the first report of radioactive I131 treatment being harmful to salivary glands due to compromised salivary compositional and oxidative profile and oral discomfort complaints.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18426826     DOI: 10.1530/EJE-07-0634

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

Review 1.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-17       Impact factor: 3.603

2.  Morphometric and functional changes of salivary gland dysfunction after radioactive iodine ablation in a murine model.

Authors:  Jeong-Seok Choi; In Suh Park; Seok-Ki Kim; Jae-Yol Lim; Young-Mo Kim
Journal:  Thyroid       Date:  2013-07-25       Impact factor: 6.568

3.  [Inflammation grading and sialoendoscopic treatment of 131I radioiodine-induced sialadenitis].

Authors:  X Li; J Z Su; Y Y Zhang; L Q Zhang; Y Q Zhang; D G Liu; G Y Yu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-06-18

4.  A Functional Scoring System Based on Salivary Gland Scintigraphy for Evaluating Salivary Gland Dysfunction Secondary to 131I therapy in Patients with Differentiated Thyroid Carcinoma.

Authors:  Yasuhiro Maruoka; Shingo Baba; Takuro Isoda; Yoshiyuki Kitamura; Koichiro Abe; Masayuki Sasaki; Hiroshi Honda
Journal:  J Clin Diagn Res       Date:  2017-08-01

5.  Total oxidant/antioxidant status in sera of patients with thyroid cancers.

Authors:  Dong Wang; Jia-Fu Feng; Ping Zeng; Yun-Hong Yang; Jun Luo; Yu-Wei Yang
Journal:  Endocr Relat Cancer       Date:  2011-12-01       Impact factor: 5.678

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.